Most insurance plans cover glucose monitors for people with diabetes, but the type of monitor, your diagnosis, and your treatment plan all affect what you’ll pay out of pocket. Standard blood glucose meters with test strips are widely covered with minimal hassle. Continuous glucose monitors (CGMs), the small wearable sensors that track blood sugar around the clock, involve more hoops but are increasingly accessible under Medicare, Medicaid, and private insurance.
Standard Blood Glucose Meters
Traditional fingerstick meters are the easiest glucose monitors to get covered. Medicare Part B covers the meter itself, test strips, lancets, and a lancet device for anyone with a diabetes diagnosis. If you use insulin, you can get up to 300 test strips and 300 lancets every three months. If you manage diabetes without insulin, that drops to 100 test strips and 100 lancets every three months. Private insurers generally follow similar patterns, though specific quantities vary by plan.
These supplies are classified as durable medical equipment, so you’ll typically pay 20% of the Medicare-approved amount after meeting your Part B deductible. Most commercial plans cover standard meters under either the medical benefit or pharmacy benefit with a modest copay.
Medicare Coverage for CGMs
Medicare covers continuous glucose monitors and their supplies when your doctor prescribes one and you meet two conditions: you take insulin or have a history of problematic low blood sugar, and your provider confirms that you (or a caregiver) have been trained to use the device properly. Before writing the prescription, your doctor must meet with you in person to evaluate whether you qualify.
This is a significant expansion from earlier rules. Medicare previously restricted CGM coverage to people on intensive insulin therapy, meaning at least three daily injections or an insulin pump, who also had to demonstrate frequent dosing adjustments based on glucose readings. Those stricter criteria locked out a large number of people who could benefit from continuous monitoring. The updated policy now includes people on basal insulin alone and non-insulin users with significant hypoglycemia episodes.
Private Insurance Criteria
Commercial insurers each set their own medical necessity standards for CGMs, but the general framework is similar across major carriers. If you’re on intensive insulin therapy (three or more daily injections or a pump), approval is relatively straightforward. UnitedHealthcare’s policy is representative: CGM is considered medically necessary for people on intensive insulin regimens, or for those on less intensive treatment plans (like basal insulin or oral medications) who have experienced dangerous low blood sugar episodes despite multiple attempts to adjust their medications.
The thresholds for “dangerous” are specific. A level 2 hypoglycemic event means blood sugar dropping below 54 mg/dL, which carries risk of cognitive problems. A level 3 event is a severe episode where you need someone else to help you, potentially life-threatening. If you’ve had one level 3 event or more than one level 2 event that didn’t resolve with medication changes, most commercial plans will approve a CGM even if you aren’t on intensive insulin.
Your insurer may also require documentation that you’ve been testing blood sugar regularly, that your treatment plan needs the data a CGM provides, and that you’re capable of using the device and responding to its alerts. These requirements vary, so checking your specific plan’s policy before your doctor submits the request saves time.
Medicaid Coverage Varies by State
As of 2023, 45 states and Washington, D.C. provide some level of CGM coverage through Medicaid. But there is no consistent policy across states, and the variation is significant. Some states cover CGMs broadly for anyone with insulin-treated diabetes. Others impose strict criteria similar to what private insurers require, including prior authorization with detailed clinical documentation.
North Carolina’s Medicaid program illustrates how involved the process can be. Initial approval requires a diabetes diagnosis, evidence that you’ve been testing blood sugar four or more times daily, that you take at least two insulin injections per day, and that your regimen requires frequent adjustment. Your doctor must also document a face-to-face visit within six months of the request. After the first authorization period, reauthorization requires proof that you’ve been using the CGM as prescribed and that your blood sugar control has improved. Later renewals add another in-person visit requirement. If you use an insulin pump that communicates with a CGM, the criteria are simpler.
Gestational Diabetes Coverage
Many insurers now cover CGMs for gestational diabetes, though the specifics differ. Some plans approve coverage for the duration of the pregnancy only. Others extend it up to 12 months postpartum, recognizing that blood sugar management matters during recovery and while the risk of developing type 2 diabetes is elevated. Your plan may require that you demonstrate the ability to use the device, that your provider has given you treatment guidelines, and that a recent A1C value is documented on the authorization request. Some plans also require the estimated or actual delivery date on the request form.
Pharmacy Benefit vs. Medical Benefit
How your plan classifies CGM supplies can make a real difference in your experience. When CGMs are covered under the medical benefit as durable medical equipment, getting your supplies often involves a lengthy documentation process. Your doctor submits paperwork to a DME supplier, who then handles prior authorization and ships the supplies to you. Wait times can be long, and even the best DME suppliers can’t provide same-day fulfillment. Local DME providers often don’t keep CGM products in stock.
When CGMs are covered under the pharmacy benefit, you pick them up at your local pharmacy like any other prescription. Turnaround is typically one to two days, and pharmacies that regularly stock CGM products can fill urgent needs the same day. Vermont’s Medicaid program made this switch and found that it not only improved access and speed for patients but also reduced administrative costs and gave the program better tools to track utilization and manage spending. Several other state Medicaid programs and commercial plans have moved in the same direction. If your plan covers CGMs but the process feels slow, ask whether pharmacy benefit coverage is an option.
What You’ll Pay Without Insurance
If you don’t have coverage or your claim is denied, costs vary by device. Abbott, which makes the FreeStyle Libre system, offers a copay card for commercially insured or uninsured patients who are asked to pay more than $75 for two sensors (roughly a month’s supply). Dexcom and other manufacturers run similar savings programs. Without any discount, CGM sensors typically run $75 to $300 per month depending on the brand and model. Standard fingerstick meters are far cheaper, often under $30 for the meter itself, though test strips add ongoing costs of $20 to $100 per month depending on how often you test.
Getting Prior Authorization Approved
The prior authorization process is the most common barrier between you and a covered CGM. To give your request the best chance, make sure your medical records clearly document your diabetes diagnosis, your current treatment plan including all medications and doses, your blood sugar testing history, and any hypoglycemic episodes. Your doctor will need to confirm a recent in-person visit where they evaluated your blood sugar control and determined a CGM is appropriate.
If your initial request is denied, you have the right to appeal. Denials often come down to missing documentation rather than a true lack of medical necessity. Ask your doctor’s office which specific piece of information the insurer flagged, provide it, and resubmit. Many denials are overturned on appeal when the paperwork is complete.